title: Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results.
authors.affiliation: Department of Hematology/Oncology L and A Seragnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Palandri
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Testoni
authors.forename: Simona
authors.initials: S
authors.lastname: Luatti
authors.forename: Giulia
authors.initials: G
authors.lastname: Marzocchi
authors.forename: Carmen
authors.initials: C
authors.lastname: Baldazzi
authors.forename: Monica
authors.initials: M
authors.lastname: Stacchini
authors.forename: Fausto
authors.initials: F
authors.lastname: Castagnetti
authors.forename: Massimo
authors.initials: M
authors.lastname: Breccia
authors.forename: Giorgina
authors.initials: G
authors.lastname: Specchia
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Pane
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Saglio
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinelli
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
authors.forename: Gianantonio
authors.initials: G
authors.lastname: Rosti
mesh_terms: D001549:Benzamides; D002869:Chromosome Aberrations; D002877:Chromosomes, Human / Q000235:genetics*; D018450:Disease Progression; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D009367:Neoplasm Staging; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D015996:Survival Rate; D013997:Time Factors; D014314:Trisomy / Q000235:genetics
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate